Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.
Dr. John Cush RheumNow
5 years 9 months ago
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis
Read more:
https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA
Dr. John Cush RheumNow
5 years 9 months ago
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.
https://t.co/XwxkFz66fv https://t.co/E6W3H56jps
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
Dr. John Cush RheumNow
5 years 9 months ago
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL https://t.co/kis5zry7uH
Dr. John Cush RheumNow
5 years 9 months ago
Head to RheumNow for our latest Covid-19 articles.
https://t.co/TiB7739ONL
Dr. John Cush RheumNow
5 years 9 months ago
New download available! H2H comparison chart.
https://t.co/w7tQYXn0us
Dr. John Cush RheumNow
5 years 9 months ago
Spinal Benefits Seen With Cosentyx in PsA---Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.
https://t.co/OfkQtAO9Gh https://t.co/hs3NaBjLuF
Dr. John Cush RheumNow
5 years 9 months ago
BASE: a controlled, ph 4 safety RCT of IV Belimumab (10 mg/kg) or PBO (+standard Rx) given to 4018 SLE pts over 48 wks. Found no increase in all-cause mortality and special AE: w/ very low event rates (SIE 3·75%, opportunistic infx 1·8%, cancers 0·25%) https://t.co/Zc5BqXQ038
Dr. John Cush RheumNow
5 years 9 months ago
44 patient study of sirolimus vs placebo in patients with inclusion body myositis found no difference in the primary outcome of relative knee extension strength, nor in secondary outcomes. SAE were more common w/ sirolimus 45% vs 27% in PBO https://t.co/YhnRTnaGFl
Dr. John Cush RheumNow
5 years 9 months ago
2021 Whatever it Takes
Let me be blunt. If you’re still waiting for this whole COVID thing to be over with – you’re drifting, going nowhere and you’re setting yourself up for a long hard winter, spring and summer of 2021.
Read more on the site.
https://t.co/1y172EVpwV https://t.co/W1MAKzOCJS
Dr. John Cush RheumNow
5 years 9 months ago
Nice Yale Medicine overview of MIS-C (multisystem inflammatory syndrome in children) due to COVID-19 https://t.co/oYOlJFHzuN
Dr. John Cush RheumNow
5 years 9 months ago
COVID-19 Vaccination - Phase Ib Begins
The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines.
https://t.co/7fGCnHJnvy https://t.co/AiBBW94kR5
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine. A novel trial of IV rilonacept, an IL-1 α and IL-1β cytokine trap, resulted in rapid resolution of recurrent pericarditis and to a significantly lower risk of recurrence compared to placebo.
